Baron & Budd Attorney and Shareholder Burton LeBlanc to Speak on Opioid Epidemic at American Association for Justice
BATON ROUGE, La. – November 17, 2017 – The national law firm of Baron & Budd is pleased to...READ MORE
Drug Linked to Diabetic Ketoacidosis, Several Life-Threatening Side Effects
DALLAS (Nov. 3, 2015) – The national law firm of Baron & Budd is investigating possible lawsuits involving Invokana, a diabetes drug manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. The U.S. Food and Drug Administration has warned the drug has been linked to diabetic ketoacidosis, a condition that occurs when the body produces ketones, or high levels of acids in the blood. The condition can result in several complications, including brain swelling, impaired heart function and more.
Invokana, the brand name for the drug canagliflozin, is designed to help control blood sugar levels in patients with type-2 diabetes. It is part of a class of medications referred to as SGLT2 (sodium-glucose cotransporter-2) inhibitors. In addition to Invokana, other drugs in this class include Invokamet, Glyxambi, Xigduo XR, Farxiga, and Jardiance. These drugs work to prevent high levels of blood sugar (a condition known as hyperglycemia) by assisting in the removal of excess sugar through urination.
However, the FDA issued a Safety Communication in May 2015 involving all SGLT2 inhibitors, warning they may cause diabetic ketoacidosis. The warning was issued after the agency received reports of 20 patients suffering from the condition after taking the medications. In September 2015, the FDA updated Invokana’s warning label to include information regarding a heightened risk for bone fractures as well as a reduction in bone density.
According to the Institute for Safe Medication Practices (ISMP), the FDA has received more than 450 reports of adverse events linked to use of Invokana, including kidney failure, urinary tract infections and kidney stones.
“Our firm is thoroughly investigating this matter and monitoring all developments very closely,” said Russell Budd, president and managing shareholder of the national law firm of Baron & Budd. “We will always fight passionately on behalf of patients who have been harmed by the very medications they trusted to provide them with the highest possible quality of life.”
The law firm of Baron & Budd, P.C., with offices in Dallas, Baton Rouge, New Orleans, Austin and Los Angeles, is a nationally recognized law firm with a nearly 40-year history of "Protecting What’s Right" for people, communities and businesses harmed by negligence. Baron & Budd’s size and resources enable the firm to take on large and complex cases. The firm represents individuals and government and business entities in areas as diverse as dangerous pharmaceuticals and medical devices, environmental contamination, the Gulf oil spill, financial fraud, overtime violations, deceptive advertising, automotive defects, trucking accidents, nursing home abuse, and asbestos-related illnesses such as mesothelioma.